The immunotherapy project is focused on the use of Natural Killer (NK) cells for immunotherapy of malignant diseases, in particular hematological diseases. The project is addressing the questions of cell culture media optimization to reduce interdonor variability in NK cell in vitro expansion and optimize large scale culture of NK cells. We plan to release improved cell culture vessels and growth media for specific expansion of immunologically active lymphocytes.
In the gene therapy line of work, we have constructed mutated NK cell activation receptors with potential to retarget gene-modified NK cells. Work is under way to optimize the mutants and the gene transfer system for use in primary donor cells and test their function in vitro and in murine leukemia models.
We have planned a phase I/II clinical trial for using NK cells on Acute Myeloid Leukemia, Chronic Myeloid Leukemia and Multiple Myeloma.The overall aim of the project is to develop cell-based immunotherapy for treatment of malignant diseases and facilitate its establishment in clinical practice.